BONESUPPORT HOLDING AB ( (BOEUF) ) has released its Q4 earnings. Here is a breakdown of the information BONESUPPORT HOLDING AB presented to its investors.
BONESUPPORT HOLDING AB is a company specializing in orthobiology, focusing on developing and commercializing innovative products for bone healing and infection prevention. The company operates primarily in the healthcare sector, leveraging its unique CERAMENT technology to address significant medical needs in bone grafting and infection management.
In its latest earnings report for the year ending December 2024, BONESUPPORT reported a substantial increase in net sales, with a 52% rise compared to the previous year, reaching SEK 898.7 million. The company also highlighted significant growth in its North American segment, which saw a 62% increase in sales. The gross margin improved slightly to 92.6%, reflecting the company’s strong operational performance.
Key financial metrics from the report include a notable increase in operating results, which before the effects of incentive programs reached SEK 203.9 million, up from SEK 54.1 million in the previous year. Earnings per share saw a decrease, with figures before dilution at SEK 2.04 compared to SEK 3.77 last year, primarily due to deferred tax adjustments. The company also reported a strong cash flow from operating activities, amounting to SEK 65.7 million for the year.
Looking ahead, BONESUPPORT remains optimistic about its growth prospects, particularly with the expected market approval of CERAMENT V in the US and ongoing developments in the spine segment. The company plans to continue expanding its market presence in underpenetrated regions and is investing in additional sales resources to support this growth. Management anticipates a sales growth of over 40% in constant currency for 2025, driven by continued market penetration and clinical advancements.